News | February 20, 2021
Unichem Laboratories receives ANDA approval for Apremilast Tablets
Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .
Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .
Fluphenazine Hydrochloride Tablets, USP are available in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.
posaconazole delayed-release tablets 100 mg are the generic equivalent of Noxafil.
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Medico Remedies receives order worth US$ 1,781,000
Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Relonchem receives marketing authorization for Moxonidine tablets
Subscribe To Our Newsletter & Stay Updated
